VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 100 filers reported holding VERONA PHARMA PLC in Q3 2023. The put-call ratio across all filers is 3.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,664,250 | -22.9% | 347,500 | 0.0% | 1.73% | +34.5% |
| Q2 2023 | $7,346,150 | -47.4% | 347,500 | -50.0% | 1.29% | -55.3% |
| Q1 2023 | $13,955,620 | -23.2% | 695,001 | 0.0% | 2.88% | -26.2% |
| Q4 2022 | $18,160,376 | +89.3% | 695,001 | -26.0% | 3.91% | +74.7% |
| Q3 2022 | $9,595,000 | +106.1% | 938,890 | -15.5% | 2.24% | +80.3% |
| Q2 2022 | $4,656,000 | -16.0% | 1,111,112 | 0.0% | 1.24% | -11.1% |
| Q1 2022 | $5,544,000 | -25.8% | 1,111,112 | 0.0% | 1.40% | -3.7% |
| Q4 2021 | $7,467,000 | +22.6% | 1,111,112 | 0.0% | 1.45% | +51.7% |
| Q3 2021 | $6,089,000 | -16.2% | 1,111,112 | 0.0% | 0.96% | +6.5% |
| Q2 2021 | $7,267,000 | -21.8% | 1,111,112 | 0.0% | 0.90% | -47.6% |
| Q1 2021 | $9,289,000 | +19.4% | 1,111,112 | 0.0% | 1.71% | +119.1% |
| Q4 2020 | $7,778,000 | +12.2% | 1,111,112 | 0.0% | 0.78% | -59.6% |
| Q3 2020 | $6,933,000 | +3315.3% | 1,111,112 | +2456.9% | 1.93% | +2875.4% |
| Q2 2020 | $203,000 | – | 43,456 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |